Early Experience With Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors In Patients Treated In An Outpatient Lipid Clinic

1. Stone, NJ et al. 2013 ACC/AHA guideline on treatment of blood cholesterol to reduce atheroseclerotic cardiovascular disease. Circulation. 2013;129:S1-S45 2. Jacobson TA, Ito MK, Maki KC, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 executive summary. J Clin Lipidol. 2014;8(5):473-88 3. Robinson JG, Goldberg AC. Treatment of adults with Familial Hypercholesterolemia and evidence for treatment: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011;5(3 suppl):S18–S29. 4. Praluent(R) [package insert]. Bridgewater, NJ: Regeneron Pharmaceuticals, Inc / sanofi-aventis US LLD; 2015. 5. Repatha(R) [package insert]. Thousand Oaks, CA: Amgen Inc; 2015. • Achievement of desired LDL-C and non-HDL-C reductions per current guidelines for patients with ASCVD or familial hypercholesterolemia (FH) can be challenging despite maximally tolerated statin and non-statin therapy, especially in those with statin intolerance1-3